These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11567914)

  • 1. [Oxaliplatin tolerance in the treatment of metastatic colorectal cancers].
    Bugat R
    Bull Cancer; 2001 Aug; 88 Spec No():S45-9. PubMed ID: 11567914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin in practice.
    Misset JL
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):4-7. PubMed ID: 9647612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin-related side effects: characteristics and management.
    Cassidy J; Misset JL
    Semin Oncol; 2002 Oct; 29(5 Suppl 15):11-20. PubMed ID: 12422304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of oxaliplatin in the treatment of colorectal cancer.
    Haller DG
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):15-20. PubMed ID: 11204657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oxaliplatin: a first DACH-platinum in oncology].
    Laadem A; Cvitkovic E
    Bull Cancer; 2001 Aug; 88 Spec No():S9-13. PubMed ID: 11567908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Culy CR; Clemett D; Wiseman LR
    Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect?
    James E; Podoltsev N; Salehi E; Curtis BR; Saif MW
    Clin Colorectal Cancer; 2009 Oct; 8(4):220-4. PubMed ID: 19822513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin: a review of its use in the management of metastatic colorectal cancer.
    Wiseman LR; Adkins JC; Plosker GL; Goa KL
    Drugs Aging; 1999 Jun; 14(6):459-75. PubMed ID: 10408744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
    Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
    Cassinello J; Escudero P; Salud A; Marcos F; Pujol E; Pérez-Carrión R; Colmenarejo A; González del Val R; Valero J; Oruezábal MJ; Guillem V; García I; Arcediano A; Marfà X
    Clin Colorectal Cancer; 2003 Aug; 3(2):108-12. PubMed ID: 12952567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin-safety profile: neurotoxicity.
    Grothey A
    Semin Oncol; 2003 Aug; 30(4 Suppl 15):5-13. PubMed ID: 14523789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin-induced immune pancytopenia.
    Taleghani BM; Meyer O; Fontana S; Ahrens N; Novak U; Borner MM; Salama A
    Transfusion; 2005 May; 45(5):704-8. PubMed ID: 15847658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin-related neurotoxicity: how and why?
    Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
    Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
    Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL
    BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.
    Garziera M; Virdone S; De Mattia E; Scarabel L; Cecchin E; Polesel J; D'Andrea M; Pella N; Buonadonna A; Favaretto A; Toffoli G
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28653974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oxaliplatin in combination with 5-fluoro-uracil and folinic acid as treatment of metastatic colorectal cancer].
    André T; Louvet C; Maindrault-Goebel F; Gramont AD
    Bull Cancer; 2001 Aug; 88 Spec No():S20-5. PubMed ID: 11567910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
    Hong YS; Lee SS; Kim KP; Lee JL; Kang YK; Shin SJ; Ahn JB; Jung KH; Im SA; Kim TY; Kim JH; Park YS; Kim TW
    Am J Clin Oncol; 2014 Feb; 37(1):19-23. PubMed ID: 23111359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Literature review and practical aspects on the management of oxaliplatin-associated toxicity.
    Hoff PM; Saad ED; Costa F; Coutinho AK; Caponero R; Prolla G; Gansl RC
    Clin Colorectal Cancer; 2012 Jun; 11(2):93-100. PubMed ID: 22154408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.